Brief by Shorts91NewsDesk / 07:34am on 11 Apr 2025,Friday Health & Wellness
A groundbreaking breast cancer drug, capivasertib, has been approved for NHS use in England and Wales. Developed by AstraZeneca and the Institute of Cancer Research, this twice-daily pill targets hormone receptor-positive, HER2-negative advanced breast cancer with specific genetic mutations (PIK3CA, AKT1, or PTEN), present in about half of such cases. When combined with hormone therapy fulvestrant, it doubles the time before disease progression from 3.1 to 7.3 months. Approximately 3,000 women annually could benefit. Patients like Ellen Hughes report improved quality of life and extended survival. Experts hail this as a major advancement in personalized cancer treatment, emphasizing the need for routine genetic testing to identify eligible patients. (PC: Cancer Today & YouTube)
